SOURCE: New Life Scientific, Inc.

March 28, 2006 12:49 ET

New Life Scientific and Telomolecular Announce Agreement to Conduct Clinical Studies

FREEHOLD, NJ and SACRAMENTO, CA -- (MARKET WIRE) -- March 28, 2006 --New Life Scientific, Inc. (OTC BB: NWLS) and Telomolecular Corp., today announced an arrangement to perform clinical studies.

Telomolecular has agreed to conduct key clinical studies through New Life Scientifics' wholly owned Contract Research Organizations (CRO) in the United States and Europe. The strategic decision provides Telomolecular with a more rapid and cost efficient approach to clinical study and represents an additional long-term revenue source for New Life Scientific. Through collaboration, Telomolecular's focus on the invention of pharmaceutical products that may correct degraded chromosomal telomeres and New Life Scientifics' tested stem cell therapy products, might lead to synergistic regenerative solutions to many age-associated diseases and disorders.

According to Matthew Sarad, Chief Executive Officer of Telomolecular, "We view our relationship with New Life Scientific as an essential part of an effective market strategy. Their expertise in reduced cost operating environments is really the future of smart clinical study programs."

Wieslaw J. Bochenek, M.D., Ph.D., F.A.C.P. president of New Life Scientific, Inc., said: "We are very excited about our new relationship with Telomolecular. This relationship with Telomolecular provides credence to our business model of clinical research and establishes us with a leader in the research the effects of the aging process."

About Telomolecular

Telomolecular Corp. was organized with the purpose of engineering a new class of drugs that deliver large-molecule proteins important in the treatment of aging and age-related disease across human cell membranes. By combining new large-molecule delivery technologies with new protein discoveries it may be possible to lengthen chromosomal telomeres in therapeutic ways. Successful therapies based on this tactic may significantly offset, and potentially reverse, many devastating age-related diseases and perhaps address many of the symptoms and signs recognized as human aging.

About New Life Scientific

New Life Scientific, Inc. acquired Novo Life Scientific, the holder of a cooperation agreement with the Institute of Molecular Biology and Genetics of the Ukrainian Academy of Sciences (IMBG). New Life Scientific, Inc. has also acquired Pharma Trials (PTI), a provider of services in the areas of clinical trials, market research and the regulatory approval of products for pharmaceutical companies and Contract Research Organizations.

Safe Harbor Statements under the Private Securities Litigation Reform Act of 1965: Those statements contained herein which are not historical are forward-looking statements, and as such, are subject to risks and uncertainties that could cause actual operating results to materially differ from those contained in the forward-looking statements. Such statements include, but are not limited to, certain delays that are beyond the company's control, with respect to market acceptance of new technologies, or product delays in the testing and evaluation of products, and other risks, as detailed in the company's periodic filings with the Securities and Exchange Commission.

Contact Information